- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01887405
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext (HEJ)
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext; the HEJ-study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 11281
- Asthma and Allergy Clinic at St Göran's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained before entering the study 1
- Prescription of EpiPen or AnaPen for at least 2 months
- Age ≥16 years
- Body weight >50 kg
- Subject willing and able to comply with study protocol
Exclusion Criteria:
- Any of the following concomitant diseases: cardiovascular disease, e.g. arrhythmias or signs of coronary atherosclerosis, heart failure, uncontrolled hypertension, uncontrolled diabetes mellitus, cancer, hyperthyroidism, severe renal impairment
- Known blood-born infection, e.g. hepatitis and/or HIV
- Concomitant treatment with medication which may potentiate the effect of adrenaline, e.g. catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase (MAO) inhibitors and tricyclic antidepressants
- Pregnancy
- Being immediate family of the investigator or study staff, defined as the investigator's/staff's spouse, parent, child, grandparent or grandchild
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Adrenaline: Session 1 Jext, 2 Epipen
Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
|
Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session. Valid for both Jext and Epipen: Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water
Other Names:
|
Active Comparator: Adrenaline: Session 1 Epipen, 2 Jext
Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
|
Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session. Valid for both Jext and Epipen: Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-inferiority of Jext compared with EpiPen for the proportion of subjects with a successful self-injection.
Time Frame: 1 day
|
The following steps were recorded as correctly done or not by the observer in a check list approach (yes/no):
If all 6 steps were performed correctly, the injection was considered as successful. These data form the basis for evaluation of the binary primary endpoint (successful injection or not). |
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate and compare the handling characteristics of two auto-injectors (Jext and EpiPen) regarding subject preference for one of the two auto-injectors over the other, the time to perform the injection and any hesitance to perform the injection
Time Frame: 1 day
|
For evaluation of the secondary endpoints, the observer assessed the following: The time used for the actuation of the injection, i.e. the time from starting to read the instructions to having injected the adrenaline as recorded by a stop watch. This time was divided into two parts:
At the end of the second session the subject was asked the following question: "Which auto-injector do you prefer?" The following responses were possible: Jext / EpiPen / I don't have any preference for any of the auto-injectors. The preference is a secondary endpoint. |
1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of instructions and AEs
Time Frame: 1 day
|
After the injection the subject evaluated the package of instructions (leaflet as well as the information on the auto-injector) for the following (yes/no): Were the instructions concise? Were the instructions comprehensible? Do you have any further questions concerning the instructions or do you see any lack of clarity? These have been assessed as other endpoints. Safety assessments included recording of all AEs and serious adverse events (SAEs) were done. |
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Victoria Strand, MD Phd, Asthma and Allergy Clinic at St Göran's Hospital, Stockholm, Sweden
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Epinephrine
- Racepinephrine
- Epinephryl borate
Other Study ID Numbers
- JX-A-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Handling of Auto-injectors
-
Medical College of WisconsinCompletedCancer | Effects of Chemotherapy | Unspecified Complication of Bone Marrow Transplant | Auto Immune DiseaseUnited States
-
Centre Hospitalier Universitaire DijonCompletedQuality of Life | Systemic Auto-immune DiseasesFrance
-
Sri Manakula Vinayagar Medical College and HospitalUnknownDrinking Water Handling Practice | Knowledge of Water Borne Diseases | Bacteriological Quality of WaterIndia
-
Hospices Civils de LyonRecruitingNMDAR Antibody-associated Auto-immune EncephalitisFrance
-
Autolus LimitedEnrolling by invitationMultiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and PediatricUnited Kingdom
Clinical Trials on Adrenaline auto-injector
-
University of PennsylvaniaNovartisRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingChronic Rhinosinusitis With Nasal PolypsItaly
-
Centocor, Inc.Quintiles, Inc.CompletedRheumatoid Arthritis | Psoriasis | Psoriatic Arthritis | Ankylosing SpondylitisUnited States
-
University of WashingtonNovo Nordisk A/SNot yet recruitingDiabetes Mellitus, Type 2 | Stroke (CVA) or Transient Ischemic AttackUnited States
-
Regeneron PharmaceuticalsSanofiCompletedEczema, Atopic | Atopic DisordersUnited States
-
Hoffmann-La RocheCompleted
-
Imperial College Healthcare NHS TrustImperial College LondonActive, not recruitingCarotid Artery StenosisUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Withdrawn
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States